🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

11 results for “rifaximin” Clear

  1. RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE

    Takeda Pharmaceuticals International AG

    Active Chronic Pouchitis

    phase 3 small molecule active

    1 trial

  2. Rifaximin

    First Tracks Biotherapeutics

    Crohn Disease

    phase 3 small molecule active

    1 trial

  3. Normix 200 mg compresse rivestite con film, The placebo is a film-coated oral tablet designed to be comparable in appearance, administration, and handling to the investigational medicinal product (rifaximin 200 mg film-coated tablets), while containing no active pharmaceutical ingredient. The placebo consists exclusively of commonly used pharmaceutical excipients with established safety profiles and is administered solely to maintain blinding in the clinical trial.

    Fondazione Telethon ETS

    substance use disorder

    phase 2 small molecule active

    1 trial

  4. Rifaximin

    China SXT Pharmaceuticals

    Small Intestine Bacterial Overgrowth

    phase 2 small molecule active

    1 trial

  5. Rifaximin

    United Therapeutics Europe Ltd

    Nonalcoholic Fatty Liver Disease

    approved small molecule terminated

    1 trial

  6. Rifaximin

    First Tracks Biotherapeutics

    IBS - Irritable Bowel Syndrome

    approved small molecule active

    1 trial

  7. Rifaximin

    United Therapeutics Europe Ltd

    Clostridium Difficile Infection

    approved small molecule completed

    1 trial

  8. Rifaximin

    COLLEGIUM PHARMACEUTICAL, INC

    ACS - Acute Coronary Syndrome

    approved small molecule active

    1 trial

  9. Rifaximin

    First Tracks Biotherapeutics

    Bacterial Overgrowth Syndrome Small Bowel

    small molecule active

    1 trial

  10. Rifaximin

    United Therapeutics Europe Ltd

    Tropical Enteropathy

    small molecule completed

    1 trial

  11. Rifaximin

    United Therapeutics Europe Ltd

    Travelers' Diarrhea

    small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources